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Abstract 
 The abuse of, addiction to, and overdose from prescription opioid pain medications has 
become a leading public health concern in the United States. Overdose has become the leading 
cause of unintentional death and opioid pain medications are the leading cause of overdose. 
States are developing policy and passing legislation to address the opioid issue. Forty-nine states 
and the District of Columbia have passed legislation to develop prescription drug monitoring 
programs (PDMPs) to track opioid dispensing. These programs have the potential to improve 
public health through data collection and analysis as well as through use by prescribers as a tool 
to better understand the prescription history of their patients.  
 Unfortunately, as these are relatively new programs, it is unclear how they may best be 
utilized. Many states are passing legislation that prescribers must check the PDMP in certain 
situations prior to prescribing controlled substances. Three states – Kentucky, New York, and 
Tennessee – have had comprehensive mandates for over three years and it is possible to evaluate 
these programs and their impact on the opioid problem in these states. All three states have 
reported that the mandates have reduced “doctor shopping”. Doctor shopping is defined as a 
patient going to multiple prescribers and multiple pharmacies to obtain excessive amounts of 
opioid pain medications.  
 This paper examines the PDMP prescriber mandates in Kentucky, New York, and 
Tennessee to evaluate their cost and benefit. The conclusion is that there is no evidence that 
mandates have a significant effect on overdose deaths, prescribing of opioids, or admissions for 
treatment of opioid use disorder. Their use comes at a very high cost that may have a negative 
impact on public health by reducing the availability of medical providers.  
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Introduction 
 The United States is in the middle of an opioid crisis. The prescribing, use and abuse of 
opioid pain medications has increased dramatically over the past twenty years. Overdose deaths 
have become the leading cause of unintentional death, surpassing motor vehicle crashes in 2008 
(Warner, Hui Chen, Makuc, Anderson, & Miniño, 2011).  
 To address this, states have begun legislating programs and policies to improve the 
prescribing of opioids and reduce addiction, overdose and death. Forty-nine states have created 
prescription drug monitoring programs (PDMPs) (PDMP TTAC, 2016c). These programs record 
controlled substances dispensed by pharmacies and can be accessed by prescribers to get a better 
understanding of their patients’ prescription record. There is concern that underutilization of 
these programs will result in inappropriate prescribing leading to increase use of opioids and 
opioid overdose death (Alexander, Frattaroli, & Gielen, 2015). Many states have responded by 
creating laws making it mandatory for prescribers to check the state PDMP prior to prescribing 
controlled substances.  
 Kentucky, New York, and Tennessee have had programs that require PDMP checks in 
most situations for over three years. Reports of outcomes from these states have all been positive 
(Freeman, Goodin, Troske, & Talbert, 2015; NYSDOH, 2016; PDMP COE, 2016; TDOH, 2016) 
and several organizations have recommended that the optimal use of a PDMP includes legislated 
mandatory checks by prescribers (CDC, 2016; National Governors Association, 2016; PDMP 
TTAC, 2016b)(Alexander et al., 2015).  
 As the entire country has experienced decreased prescribing of opioids over the past several 
years and states have enacted multiple legislative efforts at the same time as mandating 
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prescriber checks, it is difficult to know if mandates in and of themselves are effective in 
reducing drug use and overdose.  
 This report will make a comprehensive evaluation of the benefits and extra-monetary costs 
of mandating prescriber checks of the PDMP.  
History of opioids 
 Humankind has used opium and its analogs for thousands of years for both good and bad. 
The Sumerians documented the cultivation and utilization of opium over five thousand years 
ago. Hippocrates wrote of using opium to treat both pain and depression (Benyamin et al., 2008). 
In the 1800s, England shipped large amounts of opium to China resulting in a crisis of addiction 
and leading to the Opium Wars. The United States began controlling the sale of opioids in 1914 
to address the national problem with opium, morphine, and heroin (Booth, 1996). America is 
currently experiencing another epidemic of opioid use and abuse that has resulted in the deaths 
of hundreds of thousands as well as the destruction of countless lives, families, and communities.  
 Opioid medications, by definition, are medications that act on the opioid receptor and have 
characteristics similar to opium. Opium is a natural product of a specific breed of poppy – 
Papaver somniferum. Opium contains 80% morphine, 15% codeine, and 5% thebaine.  
 The problem of opioid use, abuse and overdose is complex and the medical profession, local 
communities, states, and the federal government all have an important role to play to make sure 
that these medications are used appropriately. 
 Opioids were widely available in our country from the mid-1800s through the early 1900s 
until the passage of the Harrison Narcotics Tax Act of 1914. Through this act all opioid 
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medications were taxed and controlled making it much more difficult to obtain opium, morphine, 
and heroin that had previously been available over the counter (Booth, 1996).  
 The medical community recently has become much more conscious of the dangers of opioid 
medications. Opioids through the mid-1900s were only for the most severe pain and usually in a 
hospital setting. In a 1980 letter to the editor in the New England Journal of Medicine, Drs. 
Porter and Jick reported on an evaluation of over 11,000 patients in the hospital finding that use 
of opioids led to only four developing signs of addiction (Porter & Jick, 1980). In 1986, a case 
report of 38 patients by Portenoy and Foley claimed that addiction was rare in those treated for 
chronic pain (Portenoy & Foley, 1986). Following that, opioid prescribing increased every year 
(Paulozzi & Baldwin, 2012), fueled by a combination of physicians’ desire to treat their patients 
more compassionately, unethical marketing by the pharmaceutical industry (Van Zee, 2009), and 
the positive reinforcement of consuming opioids (Polunina & Bryun, 2013). Concomitantly with 
opioid prescribing, there was an increase in opioid use disorder and opioid overdose deaths. The 
CDC has shown that the increase in addiction and death is a direct result of the increase in 
prescribing of opioids (Paulozzi, Jones, Mack, & Rudd, 2011). 
 Unintentional death is the fourth leading cause of death in the United States behind cancer, 
heart disease, and lower respiratory disease. Overdose is now the leading cause of unintentional 
death, surpassing motor vehicle crashes in 2008. Most overdoses are caused by opioid pain 
medications.  
Opioid Use Disorder 
 According to the American Society of Addiction Medicine: “Addiction is a primary, chronic 
disease of brain reward, motivation, memory and related circuitry” (ASAM, 2011). Addiction to 
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opioids is called Opioid Use Disorder (OUD). OUD can result from prolonged exposure to 
opioid medications or heroin and is more common in those with risk factors. Because the use of 
opioids results in permanent changes to the brain, OUD is truly a disease of the brain and not a 
“moral failing” as many believe (Murthy, 2016).  
 Prolonged use of prescription opioids - either by prescription or illicitly - leads to changes in 
the brain that initially result in increased dopamine secretion but later result in suppression of the 
opioid receptors, decreased dopamine secretion, and neuroplastic changes.  These neuroplastic 
changes result in changes in neuronal dendrites and neuronal connections as well as changes in 
neurotransmitters (Dacher & Nugent, 2011).  Because of this, it is common for those prescribed 
chronic opioids for chronic pain to develop an opioid use disorder.  It is believed that as many as 
50% of those on chronic opioid therapy (COT) may develop OUD (Martell et al., 2007).   
 Substance use disorder is also commonly called addiction.  This is characterized by abnormal 
behavior in an effort to repeat reinforcing behavior despite negative consequences (APA, 2013).  
When this happens, those addicted to opioids may begin exhibiting unusual behaviors including 
buying opioids from other people or going to multiple doctors to obtain their medications.  
Seeing multiple providers to obtain a controlled substance is commonly known as "doctor 
shopping".  Doctor shopping does result in higher consumption of opioids leading to an 
increased risk of overdose and death. 
Prescription Drug Monitoring Programs 
History 
 Prescription drug monitoring programs are state programs that record the dispensing of 
controlled substances. New York State began the first PDMP almost 100 years ago in 1918.  This 
primarily was to monitor the use of illegal substances including heroin and cocaine.  California 
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currently has the longest continuously operating program which began in 1939.  Up until the last 
15 years, PDMPs were primarily used for law enforcement purposes.PDMPs have multiple 
functions and yet at the same time, their primary goal is often unclear. A recent survey of PDMP 
legislation revealed that only 25 (out of 49) states name a purpose (or purposes) for the PDMP. 
Of those, 60% mentioned that the purpose was to “reduce misuse or inappropriate use of 
prescription medicines”. No state legislation mentions that the purpose of the PDMP is to reduce 
or prevent opioid overdose. Forty percent of states mention a law enforcement purpose. Only 
16% mention that one purpose is “to identify patients in need of treatment or counseling” (Davis, 
Johnston, & Pierce, 2015).  
 Most would agree that a primary utility of a PDMP is as a tool enabling prescribers to 
provide better care to their patients. The question remains as to how we measure better care. 
What are the outcomes that we should measure to determine their effectiveness? There are 
several possibilities:  
• Reduce overdose deaths. 
• Reduce the inappropriate or dangerous prescribing of controlled substances. 
• Identify people who are addicted to opioids and refer them for treatment. 
• Prevent addiction by identifying those who may be taking excessive amounts of opioids but 
are not yet addicted.  
• Identify individuals who are seeing more than one doctor to get controlled substances 
illicitly. These individuals are commonly called “doctor shoppers”.  
• Identify prescribers who are prescribing excessive numbers of opioids.  
 With these potential uses in mind, every state except Missouri has developed a PDMP. Some 
states are just beginning data collection but other states have been using their PDMP for years 
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and are working in improving functionality of the PDMP. These programs appear to have great 
potential but we have only limited data on outcomes. Kentucky, Tennessee, and New York are 
three of the older and more established programs and they all have data showing that mandating 
universal use of these databases can reduce doctor shopping. However, whether reducing doctor 
shopping is an appropriate surrogate marker for improving public health and safety is yet to be 
determined.  
Who are we protecting? 
 Nearly 19,000 people died of opioid overdose in 2014 (CDC, 2015). The combination of 
opioids with other substances – primarily benzodiazepines and alcohol – make them particularly 
deadly. Most experts believe that opioids and benzodiazepines should never be prescribed 
concurrently (Dowell, Haegerich, & Chou, 2016).  
 Of those who die from an overdose, there are three types of individuals:  
• Some are taking their medications as prescribed. Studies have shown that the higher the 
dose of opioid, the more likely to die from an overdose.  
• Some others may be getting medications innocently from more than one doctor. For 
example, they may be getting opioids from one doctor who is treating their pain and a 
benzodiazepine from another doctor treating their anxiety. While these medications are 
dangerous when taken together, the prescribing doctors may be unaware of the other 
prescription while the patient is unaware that the combination is so dangerous.  
• The final group is those individuals who are taking opioids illicitly. They are almost always 
addicted. The DSM5 says that the diagnosis of addiction “is based on a pathological 
pattern of behaviors related to use of the substance” (APA, 2013 pg 483). If addicted to 
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opioids, the risk of overdose death is 1% per year. People also die when using opioids 
recreationally before addiction develops, although this is less likely.  
 Reducing doctor shopping is usually seen as a key goal (and a measurable one) for PDMPs. 
It is generally accepted that most doctor shoppers are individuals who are addicted to the 
controlled substance and are seeing multiple providers to supply their habit. (See Figure 1 below) 
 It is unclear what percentage of the opioids prescribed are given to doctor shoppers. It is 
likely a very small percentage. A recent study looking at doctor shopping estimated that about 
0.7% of individuals who receive an opioid prescription are doctor shoppers. However, that 0.7% 
received about 4% of the opioids prescribed (McDonald & Carlson, 2013). 
 What is the ultimate outcome of preventing doctor shopping? Does it save lives? For those 
who have the disease of addiction, does it improve their survival or worsen it? Is there any data 
that can provide an answer to that? Most people with addiction need professional help to control 
the disease. Like diabetes, it is a disease that can seldom be controlled without professional 
guidance and medication. Unfortunately, research has shown that addiction treatment providers 
are in short supply (Jones, Campopiano, Baldwin, & McCance-Katz, 2015). Access to addiction 
treatment is often limited or unaffordable. If an individual with the disease of addiction has their 
supply cut off by a doctor who stops prescribing and has no access to treatment, they will turn to 
buying pills or heroin “on the street”.  
 The marked increase in the availability of heroin over the last several years has drastically 
changed the model of illicit opioid use in the United States. Ten years ago heroin was only 
available in large cities and urban markets. Today, because of the business model of Mexican 
drug cartels, heroin is ubiquitous in all areas of our country and in most locations is cheaper and 
easier to purchase than opioid pain medications (Quinones, 2015). Five years ago, the CDC 
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concluded that the number of opioid overdoses is directly related to the number of opioids 
prescribed (Paulozzi et al., 2011). With the widespread availability of heroin that is likely no 
longer the case. According to the National Survey on Drug Use and Health (NSDUH), 4 out of 5 
current heroin users report that their opioid use began with prescription opioids (Muhuri, 
Gfroerer, & Davies, 2013).  
Figure 1. Stages in the process of addiction and where PDMP is most helpful ( ) 
 
 
 
 
PDMP functionality 
 Every state (except Missouri) and the District of Columbia has their own PDMP and all 
work differently thereby making general conclusions about their utility impossible. In many 
states, it is typical for only about 30% of physicians to be registered to use the PDMP and only 
about ½ of those access the system on a regular basis (Haffajee, Jena, & Weiner, 2015). Some 
states have legislatively mandated that prescribers access the PDMP prior to prescribing in an 
effort to increase utilization. 
 While increasing use of the PDMP intuitively appears to be a good idea, there are several 
problems with the use of the PDMP to improve health.  
• Prescribers receive no training in the use of the PDMP or the interpretation of the findings. 
In some patients, the results will clearly show that they have received very few or no 
controlled substances. This will not necessarily mean it is safe to give this patient an 
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opioid prescription as there are many other factors that may make it unsafe including 
certain medical conditions and risk of addiction. It will, however, easily show that this 
individual is not doctor shopping. This is the great majority of patients. A recent survey 
of doctors in New York found that 60% of them identified suspicious results in <2% of 
their searches (Blum, Nelson, & Hoffman, 2016). 
• Other reports may clearly show that the patient is getting prescriptions from many 
prescribers and is going to multiple pharmacies. In this case the interpretation is also 
clear.  
• However, some results are not so straightforward. Some results may show minor variations 
in refill frequency or number of doctors that make it difficult to determine if this person is 
doctor shopping or on a dangerous combination of medications. There are no set rules for 
determining aberrant behavior and even experts cannot determine strict criteria (Sansone 
& Sansone, 2012).  
• The use of a PDMP will impact office work-flow and consume valuable prescriber and 
staff time. An Op-ed in the NEJM in 2012 listed the ideal characteristics of a PDMP. It 
also referenced a survey of prescribers on why they do not reference the PDMP. Time 
constraints was the primary reason cited by 73% of prescribers followed by the belief that 
it would not change care cited by 39% of providers. (Perrone & Nelson, 2012) 
Measuring outcomes. 
 Identification of doctor shoppers is often cited as an advantage and is a measured outcome of 
PDMPs. If prescribers can identify “doctor shoppers”, how effective is that at improving the 
public health? What are the possible outcomes? Do we know what happens after that? There are 
several possibilities:  
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1.The patient admits that they have the disease of addiction and the doctor can provide that 
treatment or refer to someone who does. 
2.The patient admits that they have the disease of addiction and the physician does not refer 
them but tells them to get treatment. 
3.The doctor does not discuss addiction but simply stops prescribing any more controlled 
substances.  
4.The provider “fires” the patient, discharging them from the practice. 
 A successful outcome will result only if the patient gets treatment for their OUD. This is 
most likely with scenario 1. It is less likely with scenario 2. It is highly unlikely with scenario 3 
or 4. Unfortunately, scenario 1 is the least likely as few doctors treat opioid use disorder and 
many do not know where to refer them. A recent national survey of 200 primary care doctors 
found that if doctors discovered their patients were doctor shopping, only 5% would treat their 
addiction in their own practice and only 38% would refer to treatment leaving over 50% without 
help for their life-threatening disease (Teater, 2016). Another recent study looking at actions 
taken after doctors were notified that their patients were doctor shopping found that out of 126 
patients, only three were screened for a substance use disorder and none were referred for 
treatment of a substance use disorder (Thomas et al., 2014). 
 The only benefit of identification of doctor shoppers is if they stop their drug use and get into 
treatment. We know that this seldom happens. Because opioid use disorder is seldom 
successfully treated without the use of methadone or buprenorphine, these medications must be 
readily available to those who need treatment (American Society of Addiction Medicine, 2015). 
If the treatment is not available or if the individual does not want treatment, then the only 
alternative is to find other opioid drugs. Because cost and availability are major drivers for the 
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choice of opioid, many may turn to heroin which is now cheaper and more available than many 
of the prescribed opioids (Cicero, Ellis, & Surratt, 2012).  
 Reducing opioid prescribing may be a helpful outcome that is measurable. Because of the 
natural history of addiction, reducing the supply of opioid pain medications to those who are 
already addicted my lead to a transition to heroin use (Carlson, Nahhas, Martins, & Daniulaityte, 
2016). However, if reduced prescribing occurs in those who are not addicted then there may be a 
reduction in development of opioid use disorder. Opioids prescribed to those who are not 
addicted significantly increases the risk of addiction (Edlund et al., 2014; Miech, Johnston, 
O’Malley, Keyes, & Heard, 2015; Odgers et al., 2008). 
 One goal of PDMPs may be to identify those with addiction and to get them into addiction 
treatment. If a PDMP is successful in this, there would be an increase in those entering treatment 
for OUD. The number of those entering treatment would be affected by the availability, 
accessibility, and affordability. If individuals have difficulty entering treatment, then this 
measure may see little change.  
Effectiveness of PDMPs in general 
 Several studies have shown that the implementation of a PDMP by a state may improve 
opioid prescribing and result in better outcomes (Rutkow et al., 2015). A recent study by Patrick 
et al looked at opioid overdose mortality rates in states with a PDMP. They compared death rates 
prior to implementation of the PDMP to death rates after. They found that implementation of a 
PDMP appeared to reduce the expected death rate from opioid overdose by about 1 person per 
100,000 each year (Patrick, Fry, Jones, & Buntin, 2016).  
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State Models 
 Each PDMP is developed and operated by the state or district in which it resides. Because 
of that, each PDMP is different in how it functions. Some PDMPs are more comprehensive than 
others. There are three ways that prescribers interact with PDMPs.  
Non-mandated use 
 The most common model is where the state operates a PDMP that is available to 
prescribers and dispensers (and sometimes others) and the use of the PDMP is voluntary. In this 
situation, it is desirable for practitioners to access the PDMP in a situation where they believe 
their prescribing (or dispensing) of a controlled substance may not be appropriate for a patient. 
North Carolina and Florida are two examples of states who operate with such a model.  
Proactive reporting 
 Another model of the use of a PDMP is Massachusetts where prescribers and dispensers 
may voluntarily check the database but proactive reports are also sent to prescribers if any of 
their patients are getting a dangerous combination of medications or if they are visiting multiple 
doctors to get prescriptions.  
 Currently, 29 states provide unsolicited reports to prescribers and/or to law enforcement 
(PDMP TTAC, 2016a). The goal of these reports is to identify individuals who may be engaged 
in doctor shopping or who may be on a dangerous combination or dose of medication. Reports to 
law enforcement are to identify prescribers who are prescribing excessive controlled substances 
in a way that may be illegal.  
The advantages of proactive reporting are: 
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• This does not require the prescribers to actively search the database. As most prescribers in 
voluntary programs do not check the PDMP, this will discover more patients with 
abnormal behavior or dangerous combinations of medications.  
• It does not require prescribers to interpret the data to determine if behavior is abnormal.  
Mandated use  
 Kentucky, Tennessee, and New York are examples of states that mandate review of the 
PDMP by prescribers prior to giving prescriptions of controlled substances to patients. Other 
states also mandate some form of prescriber use of the PDMP but these 3 states have had 
comprehensive mandates for three years or more. A total of 32 states now have some type of 
mandate (PDMP TTAC, 2016b). 
 There are currently 11 states that require prescribers and dispensers to check the PDMP 
under certain circumstances. There are 22 states that required prescribers only (not dispensers) to 
check the PDMP and there are 18 states that do not require prescribers or dispensers to check the 
PDMP under any circumstance. (PDMP TTAC, 2016b) 
 
 The circumstance under which prescribers are required to check the PDMP can vary 
significantly. This can minimal like the state of NC where only the medical directors of 
Outpatient Treatment Programs (OTPs) that use methadone to treat opioid use disorder are 
required to check the PDMP on admission of each patient and annually after that. Or it can be 
quite comprehensive such as Kentucky where prescribers must check the PDMP prior to writing 
any controlled substance prescription, and at least every 3 months for patients who remain on 
controlled substances.  
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 Many states have implemented multiple public health measures to address the opioid issue. 
These may include: 
• Improving access to naloxone – a critical medication that reverses opioid overdose. 
• Passing “Good Samaritan” laws that allow those who call 911 to avoid arrest if they are 
also using illegal drugs. 
• “Pill Mill” laws that reduce the number of businesses that exist simply to prescribe opioids 
and make profits with little or no regard to providing proper care to patients.  
• Developing state prescribing guidelines that reflect appropriate prescribing of controlled 
substances.  
• Improving access to medication assisted treatment (MAT) for OUD. 
 Of all policies implemented by state or federal government, mandating the use of the 
PDMP by prescribers may be the most intrusive/disruptive/costly depending on how extensive 
the mandate is.  
State Experiences 
Kentucky 
 Kentucky, for example, implemented its mandatory check requirement in July of 2012 and 
saw a dramatic rise in the use of the Kentucky All Schedule Prescription Electronic Reporting 
System (KASPER). 
Benefits of Kentucky mandate. 
 Dispensing of controlled substances decreased from 7.39 million doses in the year prior to 
the mandate, to 6.76 million doses in the year following. (PDMP COE, 2016) Kentucky also saw 
a 50% decrease in “doctor shopping” which it described as: “a patient receiving multiple 
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prescriptions from four or more different prescribers and filled at four or more different 
pharmacies within a three-month period.” (Freeman et al., 2015). 
Cost of Kentucky mandate. 
 A report to The Kentucky Cabinet for Health and Family Services in 2015 reports that 
heroin use and overdose appears to be growing faster in Kentucky than surrounding states but 
attributes this to the reformulation of OxyContin to an abuse-deterrent formulation more than the 
decreased availability of opioid pain pills (Freeman et al., 2015). As the distribution of 
reformulated OxyContin occurred across the country at the same time, it is unlikely that it would 
have affected Kentucky more that its surrounding states.    
 The year prior to HB1 there were 811,000 checks of KASPER by medical professionals. 
The year following there were 4,586,500. (PDMP COE, 2016) This represents an increase of 
3,775,500 checks. If we make the following conservative estimates:  
• The average physician salary is $200,000/yr. (Medscape source) 
• The average physician works 3000 hours/yr. 
• The average time to interrupt the visit, check KASPER, read and interpret results, and 
discuss with the patient is 1 minute.  
• The average doctor sees 4 patients per hour. 
We can then estimate that the additional 3,775,500 checks resulting from HB1 cost:  
• 62,925 hours of physician time. 
• 251,700 patient visits lost. 
• The equivalent of 21 full time physicians 
• $4,200,000 worth of physician time.  
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New York 
 New York has identified the opioid epidemic as one of its leading public health problems 
and has made multiple efforts to address this. In 2011-2013 they began an academic detailing 
project to educate prescribers in Staten Island regarding pain treatment and decreasing opioid use 
(Paone et al., 2015). In 2012, the Prescription Drug Reform Act was passed into law. This law 
contained several measures to address the opioid problem but the most significant change would 
be mandatory checks by prescribers of the NY PDMP. This began on 8/27/13. 
Benefits of the New York mandate. 
 Despite the negative opinions of users, The New York State Department of Health believes 
that mandated use has had a positive effect by reducing doctor shoppers (Hopkins, Dreyzehner, 
& O’Leary, 2014; NYSDOH, 2016). New York reports an 82% decrease in doctor shoppers by 
the end of 2014 (New York State Dept. of Health, 2016). 
Cost of New York mandate. 
 This law has not been popular with medical professionals who have generally found it 
burdensome and unhelpful.  A recent survey of NY doctors found that 40.4% thought of I-STOP 
as “rarely” or “never helpful,” and 39.4% believed it was “difficult” or “very difficult” to use. 
The study also found that most disagree with the mandate and many do not obey it (Blum et al., 
2016). 
 In the year prior to the law making it mandatory to check the NY PDMP, there were 
132,000 requests to I-STOP. In the year following there was 15,439,500. (PDMP COE, 2016) 
This represents an increase of 15,307,500. A recent survey of NY physicians estimated that it 
takes an average of 3 minutes for each check of ISTOP (Blum et al., 2016). (This likely takes 
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longer in NY than KY because KY doctors may delegate the job of retrieving the information to 
other non-MD coworkers.) Otherwise, using the other assumptions that were used for Kentucky, 
we can estimate the additional costs of the I-STOP program:  
• 765,375 hours of physician time. 
• 3,061,500 patient visits lost. 
• The equivalent of 16 full time physicians 
• $51,025,000 worth of physician time. 
Tennessee 
 Tennessee passed comprehensive Prescription Safety Act of 2012 and beginning April 1, 
2013, prescribers have been mandated to check the PDMP prior to prescribing opioid pain 
medications. Tennessee Department of Health reports that there has been a 14.3% decrease in 
morphine milligram equivalents dispensed in Tennessee from 2012 through 2015 (TDOH, 2016).  
Cost of Tennessee mandate. 
 Requests for reports by prescribers increased from 1,861,485 in 2012 to 5,062,732 in 2014 
(TDOH, 2016). This represents an increase of 3,201,247 requests per year. Using the same 
assumptions used for Kentucky, we can estimate the additional costs of the I-STOP program:  
• 53,354 hours of physician time. 
• 213,416 patient visits lost. 
• The equivalent of 17 full time physicians 
• $3,400,000 worth of physician time. 
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Outcomes: Measuring the effectiveness of mandates 
 Mandating prescribers to use the PDMP appears to be the most effective way to maximize 
utilization of the PDMP. Kentucky, New York, and Tennessee are three states that have had the 
most comprehensive mandates (most prescribers must check the PDMP for most prescriptions) 
for the longest period. Each of these three states has measured outcomes that can be compared 
with other nonmandate states to assess their value. Each state has concluded that their own 
program is successful based on reductions in doctor shopping, opioid prescribing, and/or 
prescription opioid overdose deaths.  
 Reductions in doctor shopping, however, may not be an appropriate proxy measure. It is 
unclear who doctor shops and whether this represents diversion to other individuals or addiction 
by the patient. It also appears to be infrequent and not a major contributor to opioid addiction and 
overdose.  (McDonald & Carlson, 2013) 
 The goal in any health program is to reduce morbidity and mortality. In the case of opioids, 
that means reducing the number of individuals who develop opioid use disorder and the number 
of those who die from an opioid overdose. Therefore, the most appropriate measure of the 
success of a program would likely be reduction in opioid overdose deaths. Research supports that 
individuals switch to heroin because of cost and ease of access (Mars, Bourgois, Karandinos, 
Montero, & Ciccarone, 2014). By reducing the supply of opioid pain medications to doctor 
shoppers heroin becomes cheaper and more accessible and it may inadvertently force individuals 
to change from opioid pills to heroin which has a higher risk of mortality. Therefore, overdose 
deaths must be measured counting prescription opioids as well as heroin.  
 So, the most important measure of the success of a mandated PDMP program would be to 
measure opioid overdose deaths and compare with other states that do not have a mandated 
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PDMP program. To understand the impact of the program on prescribing it is important to 
compare prescribing with other states that do not have a mandated program. Admissions to 
treatment may also be helpful to understand the status of those with OUD but this may be 
complicated by availability and affordability of treatment. It is estimated that the United States 
only has the treatment capacity to treat half of those with OUD (Jones et al., 2015). An initial 
trend showing an increase in treatment of OUD may be a positive result showing increased 
availability and accessibility of treatment.  
Outcomes for states with mandates compared to those without mandates 
 Kentucky, New York and Tennessee have had the most comprehensive prescriber mandates 
for the longest periods of time starting in 2012 or 2013. To evaluate the impact of mandatory 
PDMP checks I chose to look at opioid overdose deaths (including both opioid pain medications 
and heroin) and opioid prescribing.  
 Overdose Deaths due to opioids including heroin 
 The reduction in overdose deaths is an important measure for the success of any policy 
addressing the opioid issue. Because state policy may force some to transition to heroin and 
because most heroin users began with prescription opioids, it is important to look at opioid pain 
medications and heroin when evaluating the effect of policies and programs on overdose death. 
Table 1 shows opioid overdose deaths in the three states with mandated prescriber PDMP checks 
compared with other states from the general region. Oregon is included to show that there can be 
dramatic regional variability in overdose deaths.  
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Table 1: Overdose deaths due to Opioids including Heroin 
State 2012 2013 2014 Increase 
2012-2014 
PDMP mandate 
effective 
Mandate 
     
   Kentucky 566 551 648 14.5% 7/20/2012 
   New York 1312 1446 1537 17.1% 8/27/2013 
   Tennessee 629 675 781 24.2% 4/1/2013 
No Mandate 
     
   Florida 1261 1205 1379 9.4% 
 
   North Carolina 791 782 915 15.7% 
 
   Georgia 491 489 678 38.1% 
 
   Vermont 49 60 58 18.4% 
 
   Oregon 315 259 294 -6.7% 
 
No PDMP 
     
   Missouri 466 561 634 36.1% 
 
   Pennsylvania 756 858 994 31.5% PDMP start 6/2016 
 
Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-
2014 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999-
2014, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics 
Cooperative Program. Accessed at http://wonder.cdc.gov/mcd-icd10.html on Oct 31, 2016 8:22:08 AM 
Opioid prescriptions dispensed 
 State reports have claimed that PDMPs can be effective at reducing opioid prescribing. Some 
sources also credit mandatory checks with decreases in opioid prescribing. It is important to 
recognize that the entire United States had a decrease in prescribing from 2013-2015 of 9.8%. 
Compared to other regional states who did not mandate prescriber checks of the PDMP, 
mandating states had similar results (Table 2). It is not clear from the data that there is any 
decrease in prescribing from the mandate but there is some evidence that mandated checks 
change prescribing of opioids.  
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Table 2: Trends of number of Opioid analgesic prescriptions filled 
State 2013 2014 2015 Decrease 
2013-2015 
Date mandatory 
checks effective 
Mandate 
     
  Kentucky 4,997,389 4,900,964 4,471,521 11.8% 7/20/2012 
  New York 10,957,729 10,450,786 10,164,060 7.8% 8/27/2013 
  Tennessee 8,525,017 8,239,110 7,800,947 9.3% 4/1/2013 
      
No Mandate 
     
  Florida 13,636,391 13,413,544 12,708,441 7.3% 
 
  North Carolina 9,482,526 9,232,258 8,717,746 8.8% 
 
  Georgia 8,643,869 8,305,929 7,880,524 9.7% 
 
  Vermont 418,161 415,687 388,108 7.7% 
 
  Oregon 3,456,129 3,389,575 3,145,023 9.9% 
 
      
No PDMP 
     
  Missouri 5,755,659 5,602,998 5,217,577 10.3% 
 
  Pennsylvania 11,330,259 11,031,159 10,394,466 9.0% 
 
      
United States 251,814,805 244,462,567 227,780,915 9.8%  
 
Data provided by IMS Health. (IMS Health, 2016) 
Changes in prescribing patterns. 
 A recent review of dentists in New York showed that mandated checks for dentists decreased 
opioid prescribing by 78% (Rasubala, Pernapati, Velasquez, Burk, & Ren, 2015). It is unclear 
why this happened but likely it was reducing the first exposure of opioids to patients as dentists 
usually prescribe for acute pain instead of chronic pain. Dentists are also the biggest prescribers 
of opioids to children (Volkow, McLellan, Cotto, Karithanom, & Weiss, 2011).  
 Baehren et al looked at emergency department prescribing before and after implementation 
of a mandatory PDMP check showed that it decreased prescribing to some but increased 
prescribing to others suggesting an increase in first exposure to opioids (Baehren et al., 2010) 
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which in turn may lead to an increase in future abuse and addiction (Edlund et al., 2014; Miech 
et al., 2015; Paulozzi et al., 2012).  
Conclusion 
 Many states are trying to find the best way to utilize their PDMPs. Some states have 
mandated that prescribers request and check information from the state PDMP prior to 
prescribing opioids and other controlled substances. These states believe that this tactic must be 
successful because they have seen decreases in prescribing of opioids, opioid overdoses, and 
doctor shopping. However, reduction in doctor shopping may not be an appropriate public health 
goal as there is no clear evidence that it improves health or saves lives. While these states have 
also seen a decrease in prescribing of opioids, this reflects a national trend that is comparable to 
surrounding states. In fact, the entire nation has seen a decrease in opioid prescribing. Some of 
these states also note a decrease in opioid overdose deaths although when counted with heroin 
overdoses, their rates continue similar to other states with yearly increases.  
 The real cost of mandatory PDMP checks may not be fully understood by policy makers and 
public health officials. States that have mandated checks are utilizing large amounts of a very 
valuable resource: physician time. The development of single-focus policy that consumes so 
much physician capital is not wise. The unintended consequences that result from the lack of 
physician availability will be impossible to measure but likely will be considerable.  
 The opioid epidemic is a major public health concern in the United States. The CDC and 
others have recommended multiple public health measures to address it. Now that some policies 
have been in place for several years it is important to measure outcomes and adjust policy 
recommendations accordingly. Mandatory PDMP checks by prescribers consumes valuable 
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resources but have not provided significant improvements in outcomes. Knowing the natural 
history of opioid use disorder helps us to understand that interventions to reduce the opioid 
supply after individuals become addicted likely will not save lives as heroin is readily available 
throughout the United States. A recent study interviewed heroin users in NYC and found that the 
transition to heroin was much more likely after individuals became addicted to the opioids 
because heroin was cheaper and easier to obtain (Harocopos, Allen, & Paone, 2016). The main 
effect of mandatory PDMP checks is reducing doctor shopping which – for those with OUD – 
makes obtaining opioids more expensive and more difficult likely facilitating that change to 
heroin.  
 PDMPs can be valuable tools for the prescribing doctor. We must learn how we can best 
utilize them. Definitely, easy access can prevent overuse of physician time. They can help in the 
diagnosis of addiction which is a life-threatening disease. But when this diagnosis is made, 
treatment should be as available and affordable as any other medical treatment. They are likely 
also valuable in identifying doctors who overprescribe opioids. 
 The opioid epidemic is complex and has multiple drivers. The root causes of income 
inequality and poverty must be mentioned but are beyond the scope of this paper (Mulia, 
Schmidt, Bond, Jacobs, & Korcha, 2008; Siahpush et al., 2006). As with all epidemics, the best 
treatment is to prevent the spread of the vector. This will best result from a paradigm change to 
how we treat pain to use more effective yet less addictive medications and use opioids only 
rarely. We must also treat those who are already afflicted by opioid use disorder by improving 
availability and access to treatment.  
 There may be some technical solutions that could have an impact on opioid addiction and 
overdose: 
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• Laws that limit over-prescribing of opioids.  
• Laws and rules that increase availability and access to treatment of OUD.  
• Laws that decriminalize addiction and addiction-related behaviors and instead refer people 
to treatment. 
 Adaptive changes, however, will be needed for significant improvement. In the medical 
system, we must change how we understand and treat pain. We need to understand that the 
optimal treatment for acute pain seldom involves opioid pain medications (Teater, 2014). We 
must also understand that opioids should seldom be used for chronic pain (Dowell et al., 2016).  
 The medical community should lead adaptive change as they are the vector (prescribers) 
and the ones providing treatment for those afflicted in this epidemic. Some suggestions for 
adaptive change include:  
• Physicians in public health must present unbiased and scientific recommendations for 
treatment of pain. A great example of this is the recent CDC guidelines for treatment of 
chronic pain (Dowell et al., 2016).  
• State medical boards are tasked with protecting the public from poor health care providers. 
They must also be active in promoting safe and effective pain treatment to reduce opioid 
prescribing.  
• National medical organizations should work to destigmatize addiction and make addiction 
treatment the standard of care for primary care practices.  
 Public education will also be very important as prescribers feel the pressure of time 
constraints and patient expectations and demands which likely results in increased opioid 
prescribing (Lembke, 2012).  
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 Using both adaptive and technical solutions we can begin to reduce the morbidity and 
mortality from the opioid epidemic. But it will be important that we continue to evaluation 
interventions to understand their true cost and benefit.  
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PDMP Logic Model 
 
Resources Activities Outputs Outcomes Impact 
Prescribers Develop legislation 
Legislation for  
Mandatory 
checks 
Prescribers 
identify doctor 
shoppers 
People with 
OUD get 
treatment of 
their disease 
PDMP 
Program 
Develop 
program for 
proactive 
reports 
Proactive reports 
Prescribers refer 
those with OUD 
to treatment 
Lives saved 
PDMP  
Staff 
Educate 
prescribers on 
effective use of 
the PDMP 
Prescribers use 
PDMP 
effectively and 
appropriately 
Prescribers 
aware of unsafe 
medication 
combinations 
 
Legislators     
Medical Office 
Staff     
Public Health 
Experts     
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Addendum 
Reflections on the recent presidential election results and new era for health 
care 
 
 With the election of 2016, Donald J. Trump is will soon become president of the United 
States. It is unclear how Mr. Trump’s presidency will affect the opioid epidemic along with 
overall health care. During his campaign he made several promises that could have significant 
effects.  
 One of his key promises was to repeal and replace the Affordable Care Act which would 
increase the number of uninsured by approximately 21 million by 2018. If this happens, we may 
expect the following: 
• People needing or already involved in treatment for their opioid use disorder will not be 
able to afford it resulting in continuing or returning to active opioid use and worse 
outcomes.  
• People with insurance who are on chronic opioid therapy for pain will no longer be able to 
afford their physician or medications and will result to illicit use of prescription opioids 
or heroin.  
 The Presdient Elect also promised that he would turn Medicaid into a block grant program 
to control costs. It would then be up to each state to decide how to best treat those in their state 
with Medicaid. There would likely by wide variability on how well addiction is identified and 
treated from state to state.  
 Finally, when asked about his solution to the opioid problem, he replied that he was going 
to “build the wall” between Mexico and the United States. This really reflects his lack of 
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knowledge of addiction, the opioid problem, and root causes. Hopefully, as president he will 
expand his knowledge and his plan to address opioid abuse, addiction, and overdose.  
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